These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10622675)

  • 41. Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs.
    Jatoi A; Kahanic SP; Frytak S; Schaefer P; Foote RL; Sloan J; Petersen RC
    Support Care Cancer; 2005 Jan; 13(1):66-9. PubMed ID: 15480814
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cracking the therapeutic nut in mild cognitive impairment: better nuts and better nutcrackers.
    Knopman DS
    Neurology; 2009 May; 72(18):1542-3. PubMed ID: 19176893
    [No Abstract]   [Full Text] [Related]  

  • 43. Donepezil plus vitamin E as a treatment in Alzheimer disease.
    Sobow T; Kloszewska I
    Alzheimer Dis Assoc Disord; 2003; 17(4):244. PubMed ID: 14657789
    [No Abstract]   [Full Text] [Related]  

  • 44. [Mild Cognitive Impairment: potential therapeutics].
    Allain H; Bentue-Ferrer D; Belliard S; Reymann JM; Djemaï M; Merienne M
    Rev Neurol (Paris); 2002; 158(10 Suppl):S35-40. PubMed ID: 12529584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update on Alzheimer's disease. Promising advances in detection and treatment.
    Burke JR; Morgenlander JC
    Postgrad Med; 1999 Oct; 106(5):85-6, 89-90, 93-4 passim. PubMed ID: 10560470
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease.
    Wang L; Harms MP; Staggs JM; Xiong C; Morris JC; Csernansky JG; Galvin JE
    Arch Neurol; 2010 Jan; 67(1):99-106. PubMed ID: 20065136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The emergence of pharmacotherapies for cognitive function in Down syndrome.
    Capone GT
    Am J Med Genet A; 2010 Dec; 152A(12):3026-7. PubMed ID: 21108389
    [No Abstract]   [Full Text] [Related]  

  • 48. [Instrumental ADL and basic ADL].
    Toba K; Kimura S; Yamada Y; Machida A; Kozaki K
    Nihon Rinsho; 2011 Oct; 69 Suppl 8():313-8. PubMed ID: 22787804
    [No Abstract]   [Full Text] [Related]  

  • 49. Therapeutics and mild cognitive impairment: current status and future directions.
    Thal LJ
    Alzheimer Dis Assoc Disord; 2003; 17 Suppl 2():S69-71. PubMed ID: 12813215
    [No Abstract]   [Full Text] [Related]  

  • 50. Carers' assessment of patients on donepezil--how reliable?
    Allington M; Salib E
    Int J Geriatr Psychiatry; 2000 Dec; 15(12):1155-7. PubMed ID: 11180476
    [No Abstract]   [Full Text] [Related]  

  • 51. Treating visual hallucinations with donepezil.
    Burke WJ; Roccaforte WH; Wengel SP
    Am J Psychiatry; 1999 Jul; 156(7):1117-8. PubMed ID: 10401470
    [No Abstract]   [Full Text] [Related]  

  • 52. Cholinesterase inhibitors are compatible with psychosocial intervention for Alzheimer disease patients suggested by neuroimaging findings.
    Meguro K
    Psychiatry Res Neuroimaging; 2017 Jan; 259():29-33. PubMed ID: 27940150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of donepezil on motor function in patients with Alzheimer disease.
    Bohnen N; Kaufer D; Hendrickson R; Ivanco L; Moore R; DeKosky S
    J Clin Psychopharmacol; 2004 Jun; 24(3):354-6. PubMed ID: 15118497
    [No Abstract]   [Full Text] [Related]  

  • 54. Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey.
    Vardigan JD; Cannon CE; Puri V; Dancho M; Koser A; Wittmann M; Kuduk SD; Renger JJ; Uslaner JM
    Psychopharmacology (Berl); 2015 Jun; 232(11):1859-66. PubMed ID: 25491927
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is the placebo control obsolete in a world after donepezil and vitamin E?
    Karlawish JH; Whitehouse PJ
    Arch Neurol; 1998 Nov; 55(11):1420-4. PubMed ID: 9823825
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia.
    Edland SD; Emond JA; Aisen PS; Petersen RC
    Alzheimer Dis Assoc Disord; 2010; 24(2):159-64. PubMed ID: 20505433
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Report of the task force on designing clinical trials in early (predementia) AD.
    Aisen PS; Andrieu S; Sampaio C; Carrillo M; Khachaturian ZS; Dubois B; Feldman HH; Petersen RC; Siemers E; Doody RS; Hendrix SB; Grundman M; Schneider LS; Schindler RJ; Salmon E; Potter WZ; Thomas RG; Salmon D; Donohue M; Bednar MM; Touchon J; Vellas B
    Neurology; 2011 Jan; 76(3):280-6. PubMed ID: 21178097
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Platelet amyloid precursor protein forms in AD: a peripheral diagnostic tool and a pharmacological target.
    Padovani A; Borroni B; Colciaghi F; Pastorino L; Archetti S; Cottini E; Caimi L; Cattabeni F; Di Luca M
    Mech Ageing Dev; 2001 Nov; 122(16):1997-2004. PubMed ID: 11589917
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Higher levels of thyroxine may predict a favorable response to donepezil treatment in patients with Alzheimer disease: a prospective, case-control study.
    Chang YS; Wu YH; Wang CJ; Tang SH; Chen HL
    BMC Neurosci; 2018 Jun; 19(1):36. PubMed ID: 29929471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improving the predictive value of interventional animal models data.
    Zeiss CJ
    Drug Discov Today; 2015 Apr; 20(4):475-82. PubMed ID: 25448761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.